Newsroom
Stay connected with all the latest news and updates from Broken String
Broken String Biosciences Files FDA Master File for INDUCE-seq® as Regulatory Expectations Rise for Genome-Wide Off-Target Analysis
Broken String Biosciences, today announced the submission of a Master File (MAF) to the U.S. Food and Drug Administration (FDA) for its INDUCE-seq® platform, marking a significant step in supporting regulatory adoption of genome-wide DNA break analysis in gene editing programs.
Broken String Biosciences Rebrands to Reflect Strategic Evolution as Demand Grows for Unbiased Genome-wide Off-target Analysis
Alongside rebranding, we have redesigned our website so researchers can easily access a comprehensive resource library and gain a clear understanding of how our INDUCE-seq platform can be applied across gene editing workflows to maximize value in development pipelines.
Broken String Biosciences Announces New Leadership to Drive Commercialization of INDUCE-seq® Platform for Gene Editing On- and Off-target Characterization
To drive the company’s commercial expansion, Terry Pizzie has been appointed as CEO, bringing extensive experience from leading and scaling global life science businesses.